CompletedPhase 3

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

United States611 participantsStarted 2004-09

Plain-language summary

The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients must have candidemia or invasive candidiasis. Exclusion Criteria: * Patients who have received an echinocandin within one month prior to study entry. * Patients who have received more than two days of prior systemic antifungal therapy for the current infection.

What they're measuring

Overall treatment success, based on the investigator's assessment of pre-defined clinical and mycological response at the End of intravenous (IV) Therapy

Timeframe: End of therapy and 6 weeks post-treatment

Trial details

NCT IDNCT00105144

SponsorAstellas Pharma Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2006-04

View on ClinicalTrials.gov More Candidiasis trials